Sofosbuvir and Daclatasvir in Mono-and HIV-coinfected Patients with Recurrent Hepatitis C After Liver Transplant

Castells, Lluís; Llaneras, Jordi; Campos-Varela, Isabel; Bilbao, Itxarone; Crespo, Manel; Len, Oscar; Rodríguez-Frías, Francisco; Charco, Ramon; Salcedo, Teresa; Esteban, Juan Ignacio; Esteban-Mur, Rafael.
Ann. hepatol ; 16(1): 86-93, Jan.-Feb. 2017. graf
Artículo en Inglés | LILACS | ID: biblio-838090

Documentos relacionados

  1.  Sofosbuvir and daclatasvir in mono- and HIV-coinfected patients with recurrent hepatitis C after liver transplant.
  2. A New Standard of Care? Standard Dose Sofosbuvir in an HCV-Infected Liver Transplant Recipient Undergoing Hemodialysis.
  3. Optimizing cardiac status in the preliver transplant candidate.
  4. Use of neural network models to predict liver transplantation waitlist mortality.
  5. Outcomes in Living Donor Compared With Deceased Donor Primary Liver Transplantation in Lower Acuity Patients With Model for End-Stage Liver Disease Scores <30.
  6. A randomized, controlled, prehabilitation intervention to maximize early recovery (PRIMER) in liver transplantation.
  7. Equity in liver transplantation: are we any closer?
  8. Survival Benefit of Split-Liver Transplantation for Pediatric and Adult Candidates.
  9. Prognostic Factors in Pediatric Early Liver Retransplantation.
  10. Reexamining "psychosocial clearance": A procedural framework for psychosocial evaluation in liver transplantation.